Overview

Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to transforming the lives of patients with rare disorders through innovative gene therapies

Our programmes will use the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders

We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy

Our mission is to transform the lives of patients with rare disorders through innovative gene therapies

Our vision is to become the leader in gene therapy for primary immune deficiencies and inherited metabolic disorders

Management Team

Orchard's Leadership team brings more than a decade of experience in the development, manufacturing and commercialization of advanced therapies for rare diseases

Mark Rothera
Mark Rothera
President & Chief Executive Officer
Stewart Craig
Stewart Craig
Chief Manufacturing Officer
Anne Dupraz-Poiseau
Anne Dupraz-Poiseau
Chief Regulatory Officer
Bobby Gaspar
Bobby Gaspar
Chief Scientific Officer
Nicolas Koebel
Nicolas Koebel
Chief of Staff & Head of Program Management
Adrien Lemoine
Adrien Lemoine
SVP Business Development & Alliance Management
Andrea Spezzi
Andrea Spezzi
Chief Medical Officer

Scientific Advisory Board

Orchard's Scientific Advisory Board brings together the world's leading scientists and clinicians in the field of gene therapy. Orchard is partnered with University College London, Great Ormond Street Hospital and University of Manchester in the United Kingdom, Genethon in France, as well as University of California Los Angeles and Boston Children's Hospital in the United States

Board of Directors

Benjamin Auspitz
Benjamin Auspitz
Bobby Gaspar
Bobby Gaspar
Alex Pasteur
Alexander Pasteur
Mark Rothera
Mark Rothera

Investors

About Baillie Gifford
  • Baillie Gifford employs over 980 people and has assets under management and advice of over £166 billion as at 30 June 2017
  • An asset management firm founded in 1908, it is headquartered in Edinburgh where most of its staff live and work
About Cowen Healthcare Investments
  • Cowen Healthcare Investments was founded to capitalize on the tremendous pace of change and innovation in the healthcare sector
  • The team has considerable biopharma investing experience and a disciplined investment history driven by deep diligence of underlying science
  • Cowen Healthcare Investments principally invests in mid- to late-stage private biopharma and digital health companies with scientifically validated targets, compounds, and technologies
  • We focus on companies with disruptive science, targeting a significant unmet medical need, and experienced management teams
About F-Prime Capital
  • Leading international venture capital firm with focus on healthcare and life sciences, with over $1 billion under management in healthcare-dedicated venture funds
  • F-Prime is backed by Fidelity Investments ($5 trillion in customer assets) and has a global reach with 80 investments located in United States, Europe, Japan, China, India
  • F-Prime’s investment focus is on  bringing new products to market, with a strong interest in rare disease, gene therapy, gene editing and cell therapy
  • F-Prime companies have delivered seven products to regulatory approval
ORI Capital
About ORI Capital
  • ORI Healthcare Fund is a US $200 million venture capital fund focused on investing in innovative companies with disruptive technologies in the healthcare industry globally
  • The fund is founded by Ms. Simone (Hong Fang) Song, former investment banker and head of China Healthcare at Goldman Sachs. The team consists mostly of former Goldman Sachs bankers and healthcare scientists
  • The Fund is supported by a network of most renowned scientists, practitioners and entrepreneurs
About Temasek
  • Incorporated in 1974, Temasek is an investment company headquartered in Singapore. Supported by 10 offices internationally, Temasek owns a $275 billion (US$197 billion) portfolio as of 31 March 2017, mainly in Singapore and the rest of Asia
  • Our portfolio covers a broad spectrum of industries: financial services; telecommunications, media & technology; transportation & industrials; consumer & real estate; life sciences & agribusiness; as well as energy & resources. Our investment activities are guided by four investment themes and the long-term trends they represent: Transforming Economies; Growing Middle Income Populations; Deepening Comparative Advantages; and Emerging Champions
  • For more information on Temasek, please visit www.temasek.com.sg
UCL Technology Fund
UCL Technology Fund
  • The UCL Technology Fund is dedicated to investing in intellectual property commercialisation opportunities arising from University College London’s world-class research base, focusing in particular on the physical and life sciences.
  • The Fund is managed by Albion Capital, one of the largest independent venture capital investors in the UK in collaboration with UCL Business (UCLB), building on their 15-year relationship.
  • UCLB is the commercialisation company of University College London and its partner NHS Trusts, bringing to market world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.